^
No biomarker
|
Follicular Lymphoma
|
No biomarker
|
Follicular Lymphoma
|
tisagenlecleucel-T Sensitive: A1 - Approval
Novartis Press Release - Today (NewA1)
|
tisagenlecleucel-T Sensitive: A1 - Approval
Novartis Press Release - Today - (New A1)
|
No biomarker
|
Esophageal Squamous Cell Carcinoma
|
No biomarker
|
Esophageal Squamous Cell Carcinoma
|
nivolumab Sensitive: A1 - Approval
Bristol-Myers Squibb Press Release - 1 day (NewA1)
|
nivolumab Sensitive: A1 - Approval
Bristol-Myers Squibb Press Release - 1 day - (New A1)
|
No biomarker
|
Esophageal Squamous Cell Carcinoma
|
No biomarker
|
Esophageal Squamous Cell Carcinoma
|
nivolumab + ipilimumab Sensitive: A1 - Approval
Bristol-Myers Squibb Press Release - 1 day (NewA1)
|
nivolumab + ipilimumab Sensitive: A1 - Approval
Bristol-Myers Squibb Press Release - 1 day - (New A1)
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
pemetrexed Sensitive: A1 - Approval
FDA - 2 days (NewA1)
|
pemetrexed Sensitive: A1 - Approval
FDA - 2 days - (New A1)
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
ciltacabtagene autoleucel Sensitive: A1 - Approval
J&J Press Release - 2 days (NewA1)
|
ciltacabtagene autoleucel Sensitive: A1 - Approval
J&J Press Release - 2 days - (New A1)
|
No biomarker
|
Malignant Pleural Mesothelioma
|
No biomarker
|
Malignant Pleural Mesothelioma
|
cisplatin + pemetrexed Sensitive: A1 - Approval
FDA - 2 days (NewA1)
|
cisplatin + pemetrexed Sensitive: A1 - Approval
FDA - 2 days - (New A1)
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
cisplatin + pemetrexed Sensitive: A1 - Approval
FDA - 2 days (NewA1)
|
cisplatin + pemetrexed Sensitive: A1 - Approval
FDA - 2 days - (New A1)
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
pembrolizumab Sensitive: A1 - Approval
FDA - 2 days (NewA1)
|
pembrolizumab Sensitive: A1 - Approval
FDA - 2 days - (New A1)
|
PD-L1 expression
|
NSCLC
|
PD-L1 expression
|
NSCLC
|
atezolizumab Sensitive: A1 - Approval
Chugai Press Release - 2 days (NewA1)
|
atezolizumab Sensitive: A1 - Approval
Chugai Press Release - 2 days - (New A1)
|
ALK positive
|
NSCLC
|
ALK positive
|
NSCLC
|
alectinib Sensitive: A1 - Approval
Cancer Med - 2 days (NewA1)
|
alectinib Sensitive: A1 - Approval
Cancer Med - 2 days - (New C3)
|
NTRK3 fusion
|
Solid Tumor
|
NTRK3 fusion
|
Solid Tumor
|
entrectinib Sensitive: A1 - Approval
ASCO 2022 - 2 days (NewA1)
|
entrectinib Sensitive: A1 - Approval
ASCO 2022 - 2 days - (New C3)
|
NTRK1 fusion
|
Solid Tumor
|
NTRK1 fusion
|
Solid Tumor
|
entrectinib Sensitive: A1 - Approval
ASCO 2022 - 2 days (NewA1)
|
entrectinib Sensitive: A1 - Approval
ASCO 2022 - 2 days - (New C3)
|
NTRK2 fusion
|
Solid Tumor
|
NTRK2 fusion
|
Solid Tumor
|
entrectinib Sensitive: A1 - Approval
ASCO 2022 - 2 days (NewA1)
|
entrectinib Sensitive: A1 - Approval
ASCO 2022 - 2 days - (New C3)
|
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
PD-L1 expression
|
Gastroesophageal Junction Adenocarcinoma
|
nivolumab + ipilimumab Sensitive: C1 - Off-label
ASCO 2022 - 2 days (NewC1)
|
nivolumab + ipilimumab Sensitive: C1 - Off-label
ASCO 2022 - 2 days - (New C3)
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
ARX788 Sensitive: C2 – Inclusion Criteria
Clin Cancer Res - 2 days (NewC2)
|
ARX788 Sensitive: C2 – Inclusion Criteria
Clin Cancer Res - 2 days - (New C3)
|
CLDN18.2 positive
|
Solid Tumor
|
CLDN18.2 positive
|
Solid Tumor
|
MIL93 Sensitive: C2 – Inclusion Criteria
ASCO 2022 - 2 days (NewC2)
|
MIL93 Sensitive: C2 – Inclusion Criteria
ASCO 2022 - 2 days - (New C3)
|
HER-2 amplification
|
Solid Tumor
|
HER-2 amplification
|
Solid Tumor
|
trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria
ASCO 2022 - 2 days (NewC2)
|
trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria
ASCO 2022 - 2 days - (New C3)
|
PD-L1 expression
|
Gastric Cancer
|
PD-L1 expression
|
Gastric Cancer
|
durvalumab + AZD6738 Sensitive: C3 – Early Trials
ASCO 2022 - 2 days (NewC3)
|
durvalumab + AZD6738 Sensitive: C3 – Early Trials
ASCO 2022 - 2 days - (New C3)
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
tislelizumab + ZW25 Sensitive: C3 – Early Trials
ASCO 2022 - 2 days (NewC3)
|
tislelizumab + ZW25 Sensitive: C3 – Early Trials
ASCO 2022 - 2 days - (New C3)
|
HER-2 positive
|
Gastric Cancer
|
HER-2 positive
|
Gastric Cancer
|
tislelizumab + ZW25 Sensitive: C3 – Early Trials
ASCO 2022 - 2 days (NewC3)
|
tislelizumab + ZW25 Sensitive: C3 – Early Trials
ASCO 2022 - 2 days - (New C3)
|
HER-2 expression
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 expression
|
Gastroesophageal Junction Adenocarcinoma
|
KN026 Sensitive: C3 – Early Trials
ASCO 2022 - 2 days (NewC3)
|
KN026 Sensitive: C3 – Early Trials
ASCO 2022 - 2 days - (New C3)
|
HER-2 expression
|
Gastric Cancer
|
HER-2 expression
|
Gastric Cancer
|
KN026 Sensitive: C3 – Early Trials
ASCO 2022 - 2 days (NewC3)
|
KN026 Sensitive: C3 – Early Trials
ASCO 2022 - 2 days - (New C3)
|
IDH1 mutation
|
AML
|
IDH1 mutation
|
AML
|
ivosidenib Sensitive: A1 - Approval
Servier Press Release - 3 days (NewA1)
|
ivosidenib Sensitive: A1 - Approval
Servier Press Release - 3 days - (New A1)
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
polatuzumab vedotin Sensitive: A2 - Guideline
Roche Press Release - 3 days (NewA2)
|
polatuzumab vedotin Sensitive: A2 - Guideline
Roche Press Release - 3 days - (New B)
|
PD-L1 expression
|
Triple Negative Breast Cancer
|
PD-L1 expression
|
Triple Negative Breast Cancer
|
pembrolizumab Sensitive: A1 - Approval
NICE - 3 days (NewA1)
|
pembrolizumab Sensitive: A1 - Approval
NICE - 3 days - (New A2)
|
NRG1 fusion
|
Solid Tumor
|
NRG1 fusion
|
Solid Tumor
|
MM-121 Sensitive: B - Late Trials
Elevation Oncology Press Release - 3 days (NewB)
|
MM-121 Sensitive: B - Late Trials
Elevation Oncology Press Release - 3 days - (New B)
|
No biomarker
|
Marginal Zone Lymphoma
|
No biomarker
|
Marginal Zone Lymphoma
|
rituximab + lenalidomide Sensitive: A1 - Approval
FDA - 4 days (NewA1)
|
rituximab + lenalidomide Sensitive: A1 - Approval
FDA - 4 days - (New A1)
|
No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
lenalidomide Sensitive: A1 - Approval
FDA - 4 days (NewA1)
|
lenalidomide Sensitive: A1 - Approval
FDA - 4 days - (New A1)
|
No biomarker
|
Follicular Lymphoma
|
No biomarker
|
Follicular Lymphoma
|
rituximab + lenalidomide Sensitive: A1 - Approval
FDA - 4 days (NewA1)
|
rituximab + lenalidomide Sensitive: A1 - Approval
FDA - 4 days - (New A1)
|
No biomarker
|
Triple Negative Breast Cancer
|
No biomarker
|
Triple Negative Breast Cancer
|
pembrolizumab Sensitive: A1 - Approval
Merck (MSD) Press Release - 4 days (NewA1)
|
pembrolizumab Sensitive: A1 - Approval
Merck (MSD) Press Release - 4 days - (New A1)
|
EGFR exon 20 insertion
|
NSCLC
|
EGFR exon 20 insertion
|
NSCLC
|
Angiogenesis inhibitor Sensitive: C3 – Early Trials
Cancer Med - 4 days (NewC3)
|
Angiogenesis inhibitor Sensitive: C3 – Early Trials
Cancer Med - 4 days - (New C3)
|
No biomarker
|
Pancreatic Cancer
|
No biomarker
|
Pancreatic Cancer
|
sunitinib Sensitive: A2 - Guideline
NCCN - 5 days (NewA2)
|
sunitinib Sensitive: A2 - Guideline
NCCN - 5 days - (New A2)
|
No biomarker
|
Pancreatic Cancer
|
No biomarker
|
Pancreatic Cancer
|
temozolomide Sensitive: A2 - Guideline
NCCN - 5 days (NewA2)
|
temozolomide Sensitive: A2 - Guideline
NCCN - 5 days - (New A2)
|
FOLR1 overexpression
|
Ovarian Cancer
|
FOLR1 overexpression
|
Ovarian Cancer
|
IMGN 853 Sensitive: B - Late Trials
Immunogen Press Release - 5 days (NewB)
|
IMGN 853 Sensitive: B - Late Trials
Immunogen Press Release - 5 days - (New B)
|
ALK positive
|
NSCLC
|
ALK positive
|
NSCLC
|
lorlatinib Sensitive: A1 - Approval
J Clin Oncol - 5 days (NewA1)
|
lorlatinib Sensitive: A1 - Approval
J Clin Oncol - 5 days - (New B)
|
EGFR mutation
|
NSCLC
|
EGFR mutation
|
NSCLC
|
EGFR inhibitor + Angiogenesis inhibitor Sensitive: C3 – Early Trials
BMC Cancer - 5 days (NewC3)
|
EGFR inhibitor + Angiogenesis inhibitor Sensitive: C3 – Early Trials
BMC Cancer - 5 days - (New C3)
|
No biomarker
|
Astrocytoma
|
No biomarker
|
Astrocytoma
|
carmustine Sensitive: A1 - Approval
FDA - 1 week (NewA1)
|
carmustine Sensitive: A1 - Approval
FDA - 1 week - (New A1)
|
No biomarker
|
Ependymoma
|
No biomarker
|
Ependymoma
|
carmustine Sensitive: A1 - Approval
FDA - 1 week (NewA1)
|
carmustine Sensitive: A1 - Approval
FDA - 1 week - (New A1)
|
No biomarker
|
Medulloblastoma
|
No biomarker
|
Medulloblastoma
|
carmustine Sensitive: A1 - Approval
FDA - 1 week (NewA1)
|
carmustine Sensitive: A1 - Approval
FDA - 1 week - (New A1)
|
No biomarker
|
HL
|
No biomarker
|
HL
|
carmustine Sensitive: A1 - Approval
FDA - 1 week (NewA1)
|
carmustine Sensitive: A1 - Approval
FDA - 1 week - (New A1)
|
No biomarker
|
NHL
|
No biomarker
|
NHL
|
carmustine Sensitive: A1 - Approval
FDA - 1 week (NewA1)
|
carmustine Sensitive: A1 - Approval
FDA - 1 week - (New A1)
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
selinexor Sensitive: A1 - Approval
Karyopharm Press Release - 1 week (NewA1)
|
selinexor Sensitive: A1 - Approval
Karyopharm Press Release - 1 week - (New B)
|
No biomarker
|
Melanoma
|
No biomarker
|
Melanoma
|
pembrolizumab Sensitive: A1 - Approval
Merck (MSD) Press Release - 1 week (NewA1)
|
pembrolizumab Sensitive: A1 - Approval
Merck (MSD) Press Release - 1 week - (New B)
|
No biomarker
|
Glioma
|
No biomarker
|
Glioma
|
carmustine Sensitive: A1 - Approval
FDA - 1 week (NewA1)
|
carmustine Sensitive: A1 - Approval
FDA - 1 week - (New A1)
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
carmustine Sensitive: A1 - Approval
FDA - 1 week (NewA1)
|
carmustine Sensitive: A1 - Approval
FDA - 1 week - (New A1)
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
sugemalimab Sensitive: A1 - Approval
CStone Pharma Press Release - 1 week (NewA1)
|
sugemalimab Sensitive: A1 - Approval
CStone Pharma Press Release - 1 week - (New B)
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
carmustine Sensitive: A1 - Approval
FDA - 1 week (NewA1)
|
carmustine Sensitive: A1 - Approval
FDA - 1 week - (New A1)
|
No biomarker
|
Juvenile Myelomonocytic Leukemia
|
No biomarker
|
Juvenile Myelomonocytic Leukemia
|
azacitidine Sensitive: A1 - Approval
FDA - 1 week (NewA1)
|
azacitidine Sensitive: A1 - Approval
FDA - 1 week - (New A1)
|
ER mutation
|
HER2 Negative Breast Cancer
|
ER mutation
|
HER2 Negative Breast Cancer
|
RAD1901 Sensitive: B - Late Trials
J Clin Oncol - 1 week (NewB)
|
RAD1901 Sensitive: B - Late Trials
J Clin Oncol - 1 week - (New B)
|
VSNL1 underexpression + CD44 underexpression
|
Gastric Cancer
|
VSNL1 underexpression + CD44 underexpression
|
Gastric Cancer
|
paclitaxel Sensitive: B - Late Trials
Sci Rep - 1 week (NewB)
|
paclitaxel Sensitive: B - Late Trials
Sci Rep - 1 week - (New B)
|
BRAF V600E
|
Cholangiocarcinoma
|
BRAF V600E
|
Cholangiocarcinoma
|
vemurafenib Sensitive: C1 - Off-label
Z Gastroenterol - 1 week (NewC1)
|
vemurafenib Sensitive: C1 - Off-label
Z Gastroenterol - 1 week - (New C4)
|
CD276 underexpression + EGFR mutation
|
LUAD
|
CD276 underexpression + EGFR mutation
|
LUAD
|
EGFR inhibitor Sensitive: C3 – Early Trials
World J Surg Oncol - 1 week (NewC3)
|
EGFR inhibitor Sensitive: C3 – Early Trials
World J Surg Oncol - 1 week - (New C3)
|
EML4-ALK fusion
|
NSCLC
|
EML4-ALK fusion
|
NSCLC
|
alectinib Sensitive: C3 – Early Trials
Int J Cancer - 1 week (NewC3)
|
alectinib Sensitive: C3 – Early Trials
Int J Cancer - 1 week - (New C3)
|
EGFR mutation + RET fusion
|
NSCLC
|
EGFR mutation + RET fusion
|
NSCLC
|
osimertinib + pralsetinib Sensitive: C3 – Early Trials
JTO Clin Res Rep - 1 week (NewC3)
|
osimertinib + pralsetinib Sensitive: C3 – Early Trials
JTO Clin Res Rep - 1 week - (New C3)
|
EML4-ALK fusion + TP53 mutation
|
NSCLC
|
EML4-ALK fusion + TP53 mutation
|
NSCLC
|
alectinib Resistant: C3 – Early Trials
Int J Cancer - 1 week (NewC3)
|
alectinib Resistant: C3 – Early Trials
Int J Cancer - 1 week - (New C3)
|
EGFR V786M
|
LUAD
|
EGFR V786M
|
LUAD
|
EGFR inhibitor Sensitive: C4 – Case Studies
Front Oncol - 1 week (NewC4)
|
EGFR inhibitor Sensitive: C4 – Case Studies
Front Oncol - 1 week - (New C4)
|
LMO7-ALK rearrangement
|
LUAD
|
LMO7-ALK rearrangement
|
LUAD
|
crizotinib Sensitive: C4 – Case Studies
Front Oncol - 1 week (NewC4)
|
crizotinib Sensitive: C4 – Case Studies
Front Oncol - 1 week - (New C4)
|
KRAS G12D
|
CRC
|
KRAS G12D
|
CRC
|
KS-58 Sensitive: D – Preclinical
Sci Rep - 1 week (NewD)
|
KS-58 Sensitive: D – Preclinical
Sci Rep - 1 week - (New D)
|
PIK3CA mutation
|
CRC
|
PIK3CA mutation
|
CRC
|
PI3K inhibitor Sensitive: D – Preclinical
Med Oncol - 1 week (NewD)
|
PI3K inhibitor Sensitive: D – Preclinical
Med Oncol - 1 week - (New D)
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
pembrolizumab Sensitive: A2 - Guideline
Int J Clin Oncol - 2 weeks (NewA2)
|
pembrolizumab Sensitive: A2 - Guideline
Int J Clin Oncol - 2 weeks - (New C3)
|
IDH2 mutation
|
AML
|
IDH2 mutation
|
AML
|
venetoclax Sensitive: A2 - Guideline
EHA 2022 - 2 weeks (NewA2)
|
venetoclax Sensitive: A2 - Guideline
EHA 2022 - 2 weeks - (New C3)
|
IDH1 mutation
|
AML
|
IDH1 mutation
|
AML
|
venetoclax Sensitive: A2 - Guideline
EHA 2022 - 2 weeks (NewA2)
|
venetoclax Sensitive: A2 - Guideline
EHA 2022 - 2 weeks - (New C3)
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
obinutuzumab + acalabrutinib Sensitive: A2 - Guideline
EHA 2022 - 2 weeks (NewA2)
|
obinutuzumab + acalabrutinib Sensitive: A2 - Guideline
EHA 2022 - 2 weeks - (New C3)
|
FLT3-TKD mutation
|
AML
|
FLT3-TKD mutation
|
AML
|
gilteritinib Sensitive: A2 - Guideline
EHA 2022 - 2 weeks (NewA2)
|
gilteritinib Sensitive: A2 - Guideline
EHA 2022 - 2 weeks - (New B)
|
FLT3-ITD mutation + FLT3-TKD mutation
|
AML
|
FLT3-ITD mutation + FLT3-TKD mutation
|
AML
|
gilteritinib Sensitive: B - Late Trials
EHA 2022 - 2 weeks (NewB)
|
gilteritinib Sensitive: B - Late Trials
EHA 2022 - 2 weeks - (New B)
|
KRAS G12C
|
NSCLC
|
KRAS G12C
|
NSCLC
|
Immunotherapy Sensitive: B - Late Trials
Oncotarget - 2 weeks (NewB)
|
Immunotherapy Sensitive: B - Late Trials
Oncotarget - 2 weeks - (New C3)
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
atezolizumab + RG6058 Sensitive: B - Late Trials
Roche Press Release - 2 weeks (NewB)
|
atezolizumab + RG6058 Sensitive: B - Late Trials
Roche Press Release - 2 weeks - (New B)
|
ROS1 positive
|
NSCLC
|
ROS1 positive
|
NSCLC
|
TPX-0005 Sensitive: B - Late Trials
Turning Point Therapeutics Press Release - 2 weeks (NewB)
|
TPX-0005 Sensitive: B - Late Trials
Turning Point Therapeutics Press Release - 2 weeks - (New B)
|
Chr amplification(1)(q21)
|
Multiple Myeloma
|
Chr amplification(1)(q21)
|
Multiple Myeloma
|
lenalidomide + isatuximab-irfc Sensitive: B - Late Trials
EHA 2022 - 2 weeks (NewB)
|
lenalidomide + isatuximab-irfc Sensitive: B - Late Trials
EHA 2022 - 2 weeks - (New B)
|
Chr t(14;16)
|
Multiple Myeloma
|
Chr t(14;16)
|
Multiple Myeloma
|
lenalidomide + isatuximab-irfc Sensitive: B - Late Trials
EHA 2022 - 2 weeks (NewB)
|
lenalidomide + isatuximab-irfc Sensitive: B - Late Trials
EHA 2022 - 2 weeks - (New B)
|
Chr t(4;14)
|
Multiple Myeloma
|
Chr t(4;14)
|
Multiple Myeloma
|
lenalidomide + isatuximab-irfc Sensitive: B - Late Trials
EHA 2022 - 2 weeks (NewB)
|
lenalidomide + isatuximab-irfc Sensitive: B - Late Trials
EHA 2022 - 2 weeks - (New B)
|
Chr del(17p)
|
Multiple Myeloma
|
Chr del(17p)
|
Multiple Myeloma
|
lenalidomide + isatuximab-irfc Sensitive: B - Late Trials
EHA 2022 - 2 weeks (NewB)
|
lenalidomide + isatuximab-irfc Sensitive: B - Late Trials
EHA 2022 - 2 weeks - (New B)
|
TMB-L
|
Follicular Lymphoma
|
TMB-L
|
Follicular Lymphoma
|
rituximab Sensitive: B - Late Trials
EHA 2022 - 2 weeks (NewB)
|
rituximab Sensitive: B - Late Trials
EHA 2022 - 2 weeks - (New B)
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
gilteritinib Sensitive: A1 - Approval
EHA 2022 - 2 weeks (NewA1)
|
gilteritinib Sensitive: A1 - Approval
EHA 2022 - 2 weeks - (New C3)
|
PD-L1 expression
|
NSCLC
|
PD-L1 expression
|
NSCLC
|
durvalumab Sensitive: A1 - Approval
Precision Oncology News - 2 weeks (NewA1)
|
durvalumab Sensitive: A1 - Approval
Precision Oncology News - 2 weeks - (New A2)
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
venetoclax + obinutuzumab Sensitive: A1 - Approval
EHA 2022 - 2 weeks (NewA1)
|
venetoclax + obinutuzumab Sensitive: A1 - Approval
EHA 2022 - 2 weeks - (New C3)
|
BCR-ABL1 T315I
|
CML
|
BCR-ABL1 T315I
|
CML
|
asciminib Sensitive: A1 - Approval
EHA 2022 - 2 weeks (NewA1)
|
asciminib Sensitive: A1 - Approval
EHA 2022 - 2 weeks - (New C3)
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
palbociclib Sensitive: A1 - Approval
Clin Cancer Res - 2 weeks (NewA1)
|
palbociclib Sensitive: A1 - Approval
Clin Cancer Res - 2 weeks - (New B)
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
midostaurin Sensitive: A1 - Approval
EHA 2022 - 2 weeks (NewA1)
|
midostaurin Sensitive: A1 - Approval
EHA 2022 - 2 weeks - (New C3)
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
BCR-ABL1 fusion
|
B Acute Lymphoblastic Leukemia
|
inotuzumab ozogamicin Sensitive: A1 - Approval
EHA 2022 - 2 weeks (NewA1)
|
inotuzumab ozogamicin Sensitive: A1 - Approval
EHA 2022 - 2 weeks - (New C3)
|
BCR-ABL1 T315I
|
CML
|
BCR-ABL1 T315I
|
CML
|
ponatinib Sensitive: A1 - Approval
EHA 2022 - 2 weeks (NewA1)
|
ponatinib Sensitive: A1 - Approval
EHA 2022 - 2 weeks - (New C3)
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
venetoclax Sensitive: A1 - Approval
EHA 2022 - 2 weeks (NewA1)
|
venetoclax Sensitive: A1 - Approval
EHA 2022 - 2 weeks - (New C3)
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
venetoclax Sensitive: A1 - Approval
EHA 2022 - 2 weeks (NewA1)
|
venetoclax Sensitive: A1 - Approval
EHA 2022 - 2 weeks - (New C3)
|
Chr del(17p)
|
CLL
|
Chr del(17p)
|
CLL
|
acalabrutinib Sensitive: A1 - Approval
EHA 2022 - 2 weeks (NewA1)
|
acalabrutinib Sensitive: A1 - Approval
EHA 2022 - 2 weeks - (New C3)
|
TP53 mutation
|
CLL
|
TP53 mutation
|
CLL
|
acalabrutinib Sensitive: A1 - Approval
EHA 2022 - 2 weeks (NewA1)
|
acalabrutinib Sensitive: A1 - Approval
EHA 2022 - 2 weeks - (New C3)
|
BCR-ABL1 fusion
|
CML
|
BCR-ABL1 fusion
|
CML
|
imatinib Sensitive: A1 - Approval
EHA 2022 - 2 weeks (NewA1)
|
imatinib Sensitive: A1 - Approval
EHA 2022 - 2 weeks - (New C4)
|
FGFR2 rearrangement
|
Cholangiocarcinoma
|
FGFR2 rearrangement
|
Cholangiocarcinoma
|
pemigatinib Sensitive: A1 - Approval
JCO Precis Oncol - 2 weeks (NewA1)
|
pemigatinib Sensitive: A1 - Approval
JCO Precis Oncol - 2 weeks - (New C3)
|
FGFR2 fusion
|
Cholangiocarcinoma
|
FGFR2 fusion
|
Cholangiocarcinoma
|
pemigatinib Sensitive: A1 - Approval
JCO Precis Oncol - 2 weeks (NewA1)
|
pemigatinib Sensitive: A1 - Approval
JCO Precis Oncol - 2 weeks - (New C3)
|
FLT3-ITD mutation
|
AML
|
FLT3-ITD mutation
|
AML
|
gilteritinib Sensitive: A2 - Guideline
EHA 2022 - 2 weeks (NewA2)
|
gilteritinib Sensitive: A2 - Guideline
EHA 2022 - 2 weeks - (New B)
|
NPM1 mutation
|
AML
|
NPM1 mutation
|
AML
|
venetoclax Sensitive: B - Late Trials
EHA 2022 - 2 weeks (NewB)
|
venetoclax Sensitive: B - Late Trials
EHA 2022 - 2 weeks - (New C3)
|
TP53 mutation
|
AML
|
TP53 mutation
|
AML
|
venetoclax Resistant: B - Late Trials
EHA 2022 - 2 weeks (NewB)
|
venetoclax Resistant: B - Late Trials
EHA 2022 - 2 weeks - (New C3)
|
BCR-ABL1 fusion
|
CML
|
BCR-ABL1 fusion
|
CML
|
ponatinib Sensitive: C1 - Off-label
EHA 2022 - 2 weeks (NewC1)
|
ponatinib Sensitive: C1 - Off-label
EHA 2022 - 2 weeks - (New C3)
|
PD-L1 expression
|
NSCLC
|
PD-L1 expression
|
NSCLC
|
atezolizumab + RG6058 Sensitive: C2 – Inclusion Criteria
Lancet Oncol - 2 weeks (NewC2)
|
atezolizumab + RG6058 Sensitive: C2 – Inclusion Criteria
Lancet Oncol - 2 weeks - (New C3)
|
RUNX1 mutation
|
AML
|
RUNX1 mutation
|
AML
|
venetoclax Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks (NewC2)
|
venetoclax Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks - (New C3)
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
quizartinib Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks (NewC2)
|
quizartinib Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks - (New C3)
|
IDH2 mutation
|
AML
|
IDH2 mutation
|
AML
|
MEN1703 Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks (NewC2)
|
MEN1703 Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks - (New C3)
|
CLDN18.2 positive
|
Gastric Cancer
|
CLDN18.2 positive
|
Gastric Cancer
|
CT041 Sensitive: C2 – Inclusion Criteria
Nat Med - 2 weeks (NewC2)
|
CT041 Sensitive: C2 – Inclusion Criteria
Nat Med - 2 weeks - (New C3)
|
FLT3 mutation
|
MDS
|
FLT3 mutation
|
MDS
|
quizartinib Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks (NewC2)
|
quizartinib Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks - (New C3)
|
CBL mutation
|
MDS
|
CBL mutation
|
MDS
|
quizartinib Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks (NewC2)
|
quizartinib Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks - (New C3)
|
U2AF1 mutation
|
AML
|
U2AF1 mutation
|
AML
|
CA-4948 Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks (NewC2)
|
CA-4948 Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks - (New C3)
|
SF3B1 mutation
|
AML
|
SF3B1 mutation
|
AML
|
CA-4948 Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks (NewC2)
|
CA-4948 Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks - (New C3)
|
SF3B1 mutation
|
MDS
|
SF3B1 mutation
|
MDS
|
CA-4948 Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks (NewC2)
|
CA-4948 Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks - (New C3)
|
U2AF1 mutation
|
MDS
|
U2AF1 mutation
|
MDS
|
CA-4948 Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks (NewC2)
|
CA-4948 Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks - (New C3)
|
CD79B mutation
|
Diffuse Large B Cell Lymphoma
|
CD79B mutation
|
Diffuse Large B Cell Lymphoma
|
zanubrutinib Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks (NewC2)
|
zanubrutinib Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks - (New C3)
|
FLT3-ITD mutation
|
AML
|
FLT3-ITD mutation
|
AML
|
HEC73543 Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks (NewC2)
|
HEC73543 Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks - (New C3)
|
CRLF2 rearrangement
|
ALL
|
CRLF2 rearrangement
|
ALL
|
T-lymphocyte cell therapy + ruxolitinib Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks (NewC2)
|
T-lymphocyte cell therapy + ruxolitinib Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks - (New C3)
|
FLT3-ITD mutation
|
AML
|
FLT3-ITD mutation
|
AML
|
quizartinib Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks (NewC2)
|
quizartinib Sensitive: C2 – Inclusion Criteria
EHA 2022 - 2 weeks - (New C3)
|
IDH1 mutation
|
AML
|
IDH1 mutation
|
AML
|
cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
cytarabine / daunorubicin liposomal formulation Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
SF3B1 mutation
|
AML
|
SF3B1 mutation
|
AML
|
venetoclax Resistant: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
venetoclax Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New D)
|
FLT3-ITD mutation
|
AML
|
FLT3-ITD mutation
|
AML
|
venetoclax Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
venetoclax Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
FLT3-ITD mutation
|
AML
|
FLT3-ITD mutation
|
AML
|
venetoclax + gilteritinib Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
venetoclax + gilteritinib Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
ASXL1 mutation
|
AML
|
ASXL1 mutation
|
AML
|
venetoclax Resistant: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
venetoclax Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
BTK C481
|
CLL
|
BTK C481
|
CLL
|
LOXO-305 Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
LOXO-305 Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
IDH1 mutation
|
AML
|
IDH1 mutation
|
AML
|
MEN1703 Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
MEN1703 Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
IGH mutation
|
CLL
|
IGH mutation
|
CLL
|
iFCG Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
iFCG Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
ETV6-NTRK3 fusion
|
Salivary Gland Cancer
|
ETV6-NTRK3 fusion
|
Salivary Gland Cancer
|
larotrectinib Sensitive: C3 – Early Trials
The Oncologist - 2 weeks (NewC3)
|
larotrectinib Sensitive: C3 – Early Trials
The Oncologist - 2 weeks - (New C3)
|
BTK C481
|
Small Lymphocytic Lymphoma
|
BTK C481
|
Small Lymphocytic Lymphoma
|
LOXO-305 Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
LOXO-305 Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
CRLF2 rearrangement
|
ALL
|
CRLF2 rearrangement
|
ALL
|
T-lymphocyte cell therapy Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
T-lymphocyte cell therapy Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
CA-4948 Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
CA-4948 Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
CD20 positive
|
Follicular Lymphoma
|
CD20 positive
|
Follicular Lymphoma
|
obinutuzumab + INCB50465 Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
obinutuzumab + INCB50465 Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
MSI-H/dMMR
|
CRC
|
MSI-H/dMMR
|
CRC
|
PD1 inhibitor Sensitive: C3 – Early Trials
Clin Cancer Res - 2 weeks (NewC3)
|
PD1 inhibitor Sensitive: C3 – Early Trials
Clin Cancer Res - 2 weeks - (New C3)
|
SF3B1 mutation
|
CLL
|
SF3B1 mutation
|
CLL
|
venetoclax Resistant: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
venetoclax Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
miR-199a overexpression
|
CML
|
miR-199a overexpression
|
CML
|
Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
TNFAIP3 mutation
|
Marginal Zone Lymphoma
|
TNFAIP3 mutation
|
Marginal Zone Lymphoma
|
zanubrutinib Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
zanubrutinib Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
MYD88 mutation
|
Marginal Zone Lymphoma
|
MYD88 mutation
|
Marginal Zone Lymphoma
|
zanubrutinib Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
zanubrutinib Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
CCND1 expression
|
Diffuse Large B Cell Lymphoma
|
CCND1 expression
|
Diffuse Large B Cell Lymphoma
|
R-CHOP Resistant: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
R-CHOP Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
BCL2 D103Y
|
CLL
|
BCL2 D103Y
|
CLL
|
venetoclax + obinutuzumab Resistant: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
venetoclax + obinutuzumab Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
BCL2 G101V
|
CLL
|
BCL2 G101V
|
CLL
|
venetoclax + rituximab Resistant: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
venetoclax + rituximab Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
BCL2 G101V
|
CLL
|
BCL2 G101V
|
CLL
|
venetoclax + obinutuzumab Resistant: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
venetoclax + obinutuzumab Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
BCL2 D103Y
|
CLL
|
BCL2 D103Y
|
CLL
|
venetoclax + rituximab Resistant: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
venetoclax + rituximab Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
SRSF2 mutation
|
AML
|
SRSF2 mutation
|
AML
|
venetoclax Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
venetoclax Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
CD19 positive
|
B Acute Lymphoblastic Leukemia
|
CD19 positive
|
B Acute Lymphoblastic Leukemia
|
T-lymphocyte cell therapy Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
T-lymphocyte cell therapy Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
CD20 positive
|
NHL
|
CD20 positive
|
NHL
|
rituximab + CC-95251 Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
rituximab + CC-95251 Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
TP53 mutation
|
MDS
|
TP53 mutation
|
MDS
|
venetoclax + decitabine/cedazuridine Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
venetoclax + decitabine / cedazuridine Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
TP53 mutation
|
CMML
|
TP53 mutation
|
CMML
|
venetoclax + decitabine/cedazuridine Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
venetoclax + decitabine / cedazuridine Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
CD79B mutation
|
Diffuse Large B Cell Lymphoma
|
CD79B mutation
|
Diffuse Large B Cell Lymphoma
|
rituximab + zanubrutinib Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
rituximab + zanubrutinib Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
CD79A mutation
|
Diffuse Large B Cell Lymphoma
|
CD79A mutation
|
Diffuse Large B Cell Lymphoma
|
zanubrutinib Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
zanubrutinib Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
CD79A mutation
|
Diffuse Large B Cell Lymphoma
|
CD79A mutation
|
Diffuse Large B Cell Lymphoma
|
rituximab + zanubrutinib Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
rituximab + zanubrutinib Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
SRSF2 mutation
|
MDS
|
SRSF2 mutation
|
MDS
|
venetoclax Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
venetoclax Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
CRLF2 overexpression
|
B Acute Lymphoblastic Leukemia
|
CRLF2 overexpression
|
B Acute Lymphoblastic Leukemia
|
inotuzumab ozogamicin Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
inotuzumab ozogamicin Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
CRLF2 overexpression
|
B Acute Lymphoblastic Leukemia
|
CRLF2 overexpression
|
B Acute Lymphoblastic Leukemia
|
blinatumomab Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
blinatumomab Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
CRLF2 overexpression
|
B Acute Lymphoblastic Leukemia
|
CRLF2 overexpression
|
B Acute Lymphoblastic Leukemia
|
blinatumomab + inotuzumab ozogamicin Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
blinatumomab + inotuzumab ozogamicin Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
SPINK2 overexpression
|
AML
|
SPINK2 overexpression
|
AML
|
DA Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
DA Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
BCR-ABL1 fusion + SET underexpression
|
CML
|
BCR-ABL1 fusion + SET underexpression
|
CML
|
Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
MAGEC1 expression
|
Multiple Myeloma
|
MAGEC1 expression
|
Multiple Myeloma
|
bortezomib Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
bortezomib Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
AP2M1 overexpression
|
Diffuse Large B Cell Lymphoma
|
AP2M1 overexpression
|
Diffuse Large B Cell Lymphoma
|
R-CHOP Resistant: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
R-CHOP Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
BCL2 positive + LGALS3 expression
|
Diffuse Large B Cell Lymphoma
|
BCL2 positive + LGALS3 expression
|
Diffuse Large B Cell Lymphoma
|
R-CHOP Resistant: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
R-CHOP Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
FLT3 mutation
|
MDS
|
FLT3 mutation
|
MDS
|
CA-4948 Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
CA-4948 Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
CD19 positive
|
NHL
|
CD19 positive
|
NHL
|
tisagenlecleucel-T Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
tisagenlecleucel-T Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
BCL2 overexpression
|
HL
|
BCL2 overexpression
|
HL
|
BEACOPP Resistant: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
BEACOPP Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
miR-16 underexpression
|
Multiple Myeloma
|
miR-16 underexpression
|
Multiple Myeloma
|
RD Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
RD Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
IGH mutation
|
CLL
|
IGH mutation
|
CLL
|
venetoclax Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks (NewC3)
|
venetoclax Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
|
ALK positive
|
NSCLC
|
ALK positive
|
NSCLC
|
ALK1 inhibitor Sensitive: C3 – Early Trials
Thorac Cancer - 2 weeks (NewC3)
|
ALK1 inhibitor Sensitive: C3 – Early Trials
Thorac Cancer - 2 weeks - (New C3)
|
CXCR3 overexpression
|
Urothelial Cancer
|
CXCR3 overexpression
|
Urothelial Cancer
|
Immunotherapy Sensitive: C3 – Early Trials
Cancer Cell Int - 2 weeks (NewC3)
|
Immunotherapy Sensitive: C3 – Early Trials
Cancer Cell Int - 2 weeks - (New C3)
|
CD8 overexpression
|
Bladder Cancer
|
CD8 overexpression
|
Bladder Cancer
|
atezolizumab Sensitive: C3 – Early Trials
Eur Urol - 2 weeks (NewC3)
|
atezolizumab Sensitive: C3 – Early Trials
Eur Urol - 2 weeks - (New C3)
|
MGMT deletion
|
CRC
|
MGMT deletion
|
CRC
|
nivolumab + ipilimumab + temozolomide Sensitive: C3 – Early Trials
J Clin Oncol - 2 weeks (NewC3)
|
nivolumab + ipilimumab + temozolomide Sensitive: C3 – Early Trials
J Clin Oncol - 2 weeks - (New C3)
|
DNMT3A mutation
|
MDS
|
DNMT3A mutation
|
MDS
|
RVU120 Sensitive: C4 – Case Studies
EHA 2022 - 2 weeks (NewC4)
|
RVU120 Sensitive: C4 – Case Studies
EHA 2022 - 2 weeks - (New C4)
|
DNMT3A mutation + NPM1 mutation
|
AML
|
DNMT3A mutation + NPM1 mutation
|
AML
|
RVU120 Sensitive: C4 – Case Studies
EHA 2022 - 2 weeks (NewC4)
|
RVU120 Sensitive: C4 – Case Studies
EHA 2022 - 2 weeks - (New C4)
|
BRAF V600E + BRAF K601_W604del
|
NSCLC
|
BRAF V600E + BRAF K601_W604del
|
NSCLC
|
trametinib + dabrafenib Sensitive: C4 – Case Studies
Cancer Genet - 2 weeks (NewC4)
|
trametinib + dabrafenib Sensitive: C4 – Case Studies
Cancer Genet - 2 weeks - (New C4)
|
KRAS G12C
|
NSCLC
|
KRAS G12C
|
NSCLC
|
selinexor + MRTX1257 Sensitive: D – Preclinical
Cancer Res Commun - 2 weeks (NewD)
|
selinexor + MRTX1257 Sensitive: D – Preclinical
Cancer Res Commun - 2 weeks - (New D)
|
KRAS G12C
|
NSCLC
|
KRAS G12C
|
NSCLC
|
sotorasib + selinexor Sensitive: D – Preclinical
Cancer Res Commun - 2 weeks (NewD)
|
sotorasib + selinexor Sensitive: D – Preclinical
Cancer Res Commun - 2 weeks - (New D)
|
EGFR mutation+ IDH1 R132H
|
NSCLC
|
EGFR mutation+ IDH1 R132H
|
NSCLC
|
erlotinib + AGI-5198 Sensitive: D – Preclinical
Cancer Med - 2 weeks (NewD)
|
erlotinib + AGI-5198 Sensitive: D – Preclinical
Cancer Med - 2 weeks - (New D)
|
NPM1 mutation
|
AML
|
NPM1 mutation
|
AML
|
NSC23766 Sensitive: D – Preclinical
EHA 2022 - 2 weeks (NewD)
|
NSC23766 Sensitive: D – Preclinical
EHA 2022 - 2 weeks - (New D)
|
FLT3 wild-type + TP53 mutation
|
AML
|
FLT3 wild-type + TP53 mutation
|
AML
|
venetoclax + gilteritinib Sensitive: D – Preclinical
EHA 2022 - 2 weeks (NewD)
|
venetoclax + gilteritinib Sensitive: D – Preclinical
EHA 2022 - 2 weeks - (New D)
|
JAK2 amplification
|
AML
|
JAK2 amplification
|
AML
|
ruxolitinib Sensitive: D – Preclinical
EHA 2022 - 2 weeks (NewD)
|
ruxolitinib Sensitive: D – Preclinical
EHA 2022 - 2 weeks - (New D)
|
MYC rearrangement + BCL2 rearrangement
|
Lymphoma
|
MYC rearrangement + BCL2 rearrangement
|
Lymphoma
|
venetoclax + DUP 785 Sensitive: D – Preclinical
EHA 2022 - 2 weeks (NewD)
|
venetoclax + DUP 785 Sensitive: D – Preclinical
EHA 2022 - 2 weeks - (New D)
|
EPOR amplification
|
AML
|
EPOR amplification
|
AML
|
ruxolitinib Sensitive: D – Preclinical
EHA 2022 - 2 weeks (NewD)
|
ruxolitinib Sensitive: D – Preclinical
EHA 2022 - 2 weeks - (New D)
|
RYBP deletion
|
MDS
|
RYBP deletion
|
MDS
|
venetoclax Sensitive: D – Preclinical
EHA 2022 - 2 weeks (NewD)
|
venetoclax Sensitive: D – Preclinical
EHA 2022 - 2 weeks - (New D)
|
TP53 R248Q
|
MDS
|
TP53 R248Q
|
MDS
|
APR-246 Sensitive: D – Preclinical
EHA 2022 - 2 weeks (NewD)
|
APR-246 Sensitive: D – Preclinical
EHA 2022 - 2 weeks - (New D)
|
TP53 R248Q
|
AML
|
TP53 R248Q
|
AML
|
APR-246 Sensitive: D – Preclinical
EHA 2022 - 2 weeks (NewD)
|
APR-246 Sensitive: D – Preclinical
EHA 2022 - 2 weeks - (New D)
|
MYC overexpression
|
Lymphoma
|
MYC overexpression
|
Lymphoma
|
brusatol Sensitive: D – Preclinical
EHA 2022 - 2 weeks (NewD)
|
brusatol Sensitive: D – Preclinical
EHA 2022 - 2 weeks - (New D)
|
MCT1 overexpression + SLC16A3 overexpression
|
Multiple Myeloma
|
MCT1 overexpression + SLC16A3 overexpression
|
Multiple Myeloma
|
metformin + syrosingopine Sensitive: D – Preclinical
EHA 2022 - 2 weeks (NewD)
|
metformin + syrosingopine Sensitive: D – Preclinical
EHA 2022 - 2 weeks - (New D)
|
No biomarker
|
Thyroid Gland Carcinoma
|
No biomarker
|
Thyroid Gland Carcinoma
|
cabozantinib tablet Sensitive: A1 - Approval
Ipsen Press Release - 3 weeks (NewA1)
|
cabozantinib tablet Sensitive: A1 - Approval
Ipsen Press Release - 3 weeks - (New A1)
|
No biomarker
|
CRC
|
No biomarker
|
CRC
|
bevacizumab Sensitive: A1 - Approval
Eur J Cancer - 3 weeks (NewA1)
|
bevacizumab Sensitive: A1 - Approval
Eur J Cancer - 3 weeks - (New B)
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
darolutamide Sensitive: A1 - Approval
Bayer Press Release - 3 weeks (NewA1)
|
darolutamide Sensitive: A1 - Approval
Bayer Press Release - 3 weeks - (New B)
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
trastuzumab + lapatinib Sensitive: A2 - Guideline
ESMO-BC 2022 - 3 weeks (NewA2)
|
trastuzumab + lapatinib Sensitive: A2 - Guideline
ESMO-BC 2022 - 3 weeks - (New C3)
|
No biomarker
|
Biliary Tract Cancer
|
No biomarker
|
Biliary Tract Cancer
|
durvalumab Sensitive: A2 - Guideline
AstraZeneca Press Release - 3 weeks (NewA2)
|
durvalumab Sensitive: A2 - Guideline
AstraZeneca Press Release - 3 weeks - (New B)
|
FLT3 mutation
|
AML
|
FLT3 mutation
|
AML
|
HM43239 Sensitive: B - Late Trials
Aptose Biosci Press Release - 3 weeks (NewB)
|
HM43239 Sensitive: B - Late Trials
Aptose Biosci Press Release - 3 weeks - (New B)
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
osimertinib Sensitive: A1 - Approval
ecancer - 3 weeks (NewA1)
|
osimertinib Sensitive: A1 - Approval
ecancer - 3 weeks - (New C3)
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
trastuzumab + tucatinib Sensitive: A1 - Approval
Mol Cancer Ther - 3 weeks (NewA1)
|
trastuzumab + tucatinib Sensitive: A1 - Approval
Mol Cancer Ther - 3 weeks - (New D)
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
trastuzumab + pertuzumab Sensitive: A1 - Approval
ESMO-BC 2022 - 3 weeks (NewA1)
|
trastuzumab + pertuzumab Sensitive: A1 - Approval
ESMO-BC 2022 - 3 weeks - (New B)
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval
FDA - 3 weeks (NewA1)
|
fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval
FDA - 3 weeks - (New A1)
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
ribociclib Sensitive: A1 - Approval
ESMO-BC 2022 - 3 weeks (NewA1)
|
ribociclib Sensitive: A1 - Approval
ESMO-BC 2022 - 3 weeks - (New B)
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
abemaciclib Sensitive: A1 - Approval
ESMO-BC 2022 - 3 weeks (NewA1)
|
abemaciclib Sensitive: A1 - Approval
ESMO-BC 2022 - 3 weeks - (New B)
|
BRCA1 mutation
|
HER2 Negative Breast Cancer
|
BRCA1 mutation
|
HER2 Negative Breast Cancer
|
olaparib Sensitive: A1 - Approval
ESMO-BC 2022 - 3 weeks (NewA1)
|
olaparib Sensitive: A1 - Approval
ESMO-BC 2022 - 3 weeks - (New B)
|
BRCA2 mutation
|
HER2 Negative Breast Cancer
|
BRCA2 mutation
|
HER2 Negative Breast Cancer
|
olaparib Sensitive: A1 - Approval
ESMO-BC 2022 - 3 weeks (NewA1)
|
olaparib Sensitive: A1 - Approval
ESMO-BC 2022 - 3 weeks - (New B)
|
CD19 positive
|
B Acute Lymphoblastic Leukemia
|
CD19 positive
|
B Acute Lymphoblastic Leukemia
|
blinatumomab Sensitive: A1 - Approval
BeiGene Press Release - 3 weeks (NewA1)
|
blinatumomab Sensitive: A1 - Approval
BeiGene Press Release - 3 weeks - (New A1)
|
NTRK2 fusion
|
Breast Cancer
|
NTRK2 fusion
|
Breast Cancer
|
entrectinib Sensitive: A2 - Guideline
ESMO-BC 2022 - 3 weeks (NewA2)
|
entrectinib Sensitive: A2 - Guideline
ESMO-BC 2022 - 3 weeks - (New C3)
|
NTRK3 fusion
|
Breast Cancer
|
NTRK3 fusion
|
Breast Cancer
|
entrectinib Sensitive: A2 - Guideline
ESMO-BC 2022 - 3 weeks (NewA2)
|
entrectinib Sensitive: A2 - Guideline
ESMO-BC 2022 - 3 weeks - (New C3)
|
NTRK1 fusion
|
Breast Cancer
|
NTRK1 fusion
|
Breast Cancer
|
entrectinib Sensitive: A2 - Guideline
ESMO-BC 2022 - 3 weeks (NewA2)
|
entrectinib Sensitive: A2 - Guideline
ESMO-BC 2022 - 3 weeks - (New C3)
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
ribociclib Sensitive: A2 - Guideline
BMC Cancer - 3 weeks (NewA2)
|
ribociclib Sensitive: A2 - Guideline
BMC Cancer - 3 weeks - (New C3)
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
palbociclib Sensitive: A2 - Guideline
BMC Cancer - 3 weeks (NewA2)
|
palbociclib Sensitive: A2 - Guideline
BMC Cancer - 3 weeks - (New C3)
|
HER-2 amplification
|
Breast Cancer
|
HER-2 amplification
|
Breast Cancer
|
tucatinib Sensitive: C2 – Inclusion Criteria
Mol Cancer Ther - 3 weeks (NewC2)
|
tucatinib Sensitive: C2 – Inclusion Criteria
Mol Cancer Ther - 3 weeks - (New D)
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
bevacizumab + osimertinib Sensitive: C2 – Inclusion Criteria
Clin Drug Investig - 3 weeks (NewC2)
|
bevacizumab + osimertinib Sensitive: C2 – Inclusion Criteria
Clin Drug Investig - 3 weeks - (New C3)
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
eftilagimod alpha Sensitive: C2 – Inclusion Criteria
ESMO-BC 2022 - 3 weeks (NewC2)
|
eftilagimod alpha Sensitive: C2 – Inclusion Criteria
ESMO-BC 2022 - 3 weeks - (New C3)
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HM 78136B Sensitive: C2 – Inclusion Criteria
ESMO-BC 2022 - 3 weeks (NewC2)
|
HM 78136B Sensitive: C2 – Inclusion Criteria
ESMO-BC 2022 - 3 weeks - (New C3)
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
tucatinib Sensitive: C2 – Inclusion Criteria
Mol Cancer Ther - 3 weeks (NewC2)
|
tucatinib Sensitive: C2 – Inclusion Criteria
Mol Cancer Ther - 3 weeks - (New D)
|
FGFR3 mutation
|
Urothelial Cancer
|
FGFR3 mutation
|
Urothelial Cancer
|
infigratinib Sensitive: C2 – Inclusion Criteria
J Urol - 3 weeks (NewC2)
|
infigratinib Sensitive: C2 – Inclusion Criteria
J Urol - 3 weeks - (New C3)
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
U3-1402 Sensitive: C2 – Inclusion Criteria
ESMO-BC 2022 - 3 weeks (NewC2)
|
U3-1402 Sensitive: C2 – Inclusion Criteria
ESMO-BC 2022 - 3 weeks - (New C3)
|
EGFR mutation
|
NSCLC
|
EGFR mutation
|
NSCLC
|
aumolertinib Sensitive: C2 – Inclusion Criteria
J Exp Clin Cancer Res - 3 weeks (NewC2)
|
aumolertinib Sensitive: C2 – Inclusion Criteria
J Exp Clin Cancer Res - 3 weeks - (New D)
|
BRAF wild-type
|
CRC
|
BRAF wild-type
|
CRC
|
anlotinib Sensitive: C2 – Inclusion Criteria
BMC Med - 3 weeks (NewC2)
|
anlotinib Sensitive: C2 – Inclusion Criteria
BMC Med - 3 weeks - (New C3)
|
HRD
|
Triple Negative Breast Cancer
|
HRD
|
Triple Negative Breast Cancer
|
cisplatin Sensitive: C2 – Inclusion Criteria
Ther Adv Med Oncol - 3 weeks (NewC2)
|
cisplatin Sensitive: C2 – Inclusion Criteria
Ther Adv Med Oncol - 3 weeks - (New C3)
|
ER positive
|
Breast Cancer
|
ER positive
|
Breast Cancer
|
abemaciclib Sensitive: C2 – Inclusion Criteria
Gan To Kagaku Ryoho - 3 weeks (NewC2)
|
abemaciclib Sensitive: C2 – Inclusion Criteria
Gan To Kagaku Ryoho - 3 weeks - (New C4)
|
PD-L1 underexpression
|
NSCLC
|
PD-L1 underexpression
|
NSCLC
|
Immunotherapy Sensitive: C3 – Early Trials
Clin Exp Immunol - 3 weeks (NewC3)
|
Immunotherapy Sensitive: C3 – Early Trials
Clin Exp Immunol - 3 weeks - (New C3)
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
Immunotherapy Sensitive: C3 – Early Trials
Clin Lung Cancer - 3 weeks (NewC3)
|
Immunotherapy Sensitive: C3 – Early Trials
Clin Lung Cancer - 3 weeks - (New C3)
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
nivolumab + fam-trastuzumab deruxtecan-nxki Sensitive: C3 – Early Trials
ESMO-BC 2022 - 3 weeks (NewC3)
|
nivolumab + fam-trastuzumab deruxtecan-nxki Sensitive: C3 – Early Trials
ESMO-BC 2022 - 3 weeks - (New C3)
|
KRAS mutation
|
Biliary Tract Cancer
|
KRAS mutation
|
Biliary Tract Cancer
|
anlotinib + APL-502 Resistant: C3 – Early Trials
Hepatology - 3 weeks (NewC3)
|
anlotinib + APL-502 Resistant: C3 – Early Trials
Hepatology - 3 weeks - (New C3)
|
TMB-H
|
Biliary Tract Cancer
|
TMB-H
|
Biliary Tract Cancer
|
anlotinib + APL-502 Sensitive: C3 – Early Trials
Hepatology - 3 weeks (NewC3)
|
anlotinib + APL-502 Sensitive: C3 – Early Trials
Hepatology - 3 weeks - (New C3)
|
MET mutation
|
NSCLC
|
MET mutation
|
NSCLC
|
Immunotherapy Resistant: C3 – Early Trials
Thorac Cancer - 3 weeks (NewC3)
|
Immunotherapy Resistant: C3 – Early Trials
Thorac Cancer - 3 weeks - (New C3)
|
MYC mutation
|
HER2 Positive Breast Cancer
|
MYC mutation
|
HER2 Positive Breast Cancer
|
trastuzumab + atezolizumab + pertuzumab Resistant: C3 – Early Trials
ESMO-BC 2022 - 3 weeks (NewC3)
|
trastuzumab + atezolizumab + pertuzumab Resistant: C3 – Early Trials
ESMO-BC 2022 - 3 weeks - (New C3)
|
HER-2 underexpression
|
Breast Cancer
|
HER-2 underexpression
|
Breast Cancer
|
eribulin mesylate Sensitive: C3 – Early Trials
ESMO-BC 2022 - 3 weeks (NewC3)
|
eribulin mesylate Sensitive: C3 – Early Trials
ESMO-BC 2022 - 3 weeks - (New C3)
|
PDSS1 overexpression
|
HCC
|
PDSS1 overexpression
|
HCC
|
Immunotherapy Resistant: C3 – Early Trials
Cancer Manag Res - 3 weeks (NewC3)
|
Immunotherapy Resistant: C3 – Early Trials
Cancer Manag Res - 3 weeks - (New C3)
|
CD8 overexpression
|
Breast Cancer
|
CD8 overexpression
|
Breast Cancer
|
paclitaxel + epirubicin Sensitive: C3 – Early Trials
ESMO-BC 2022 - 3 weeks (NewC3)
|
paclitaxel + epirubicin Sensitive: C3 – Early Trials
ESMO-BC 2022 - 3 weeks - (New C3)
|
MYC amplification + HER-2 amplification
|
HER2 Positive Breast Cancer
|
MYC amplification + HER-2 amplification
|
HER2 Positive Breast Cancer
|
trastuzumab + atezolizumab + pertuzumab Resistant: C3 – Early Trials
ESMO-BC 2022 - 3 weeks (NewC3)
|
trastuzumab + atezolizumab + pertuzumab Resistant: C3 – Early Trials
ESMO-BC 2022 - 3 weeks - (New C3)
|
RAD21 amplification
|
HER2 Positive Breast Cancer
|
RAD21 amplification
|
HER2 Positive Breast Cancer
|
trastuzumab + atezolizumab + pertuzumab Resistant: C3 – Early Trials
ESMO-BC 2022 - 3 weeks (NewC3)
|
trastuzumab + atezolizumab + pertuzumab Resistant: C3 – Early Trials
ESMO-BC 2022 - 3 weeks - (New C3)
|
MYC amplification
|
HER2 Positive Breast Cancer
|
MYC amplification
|
HER2 Positive Breast Cancer
|
trastuzumab + atezolizumab + pertuzumab Resistant: C3 – Early Trials
ESMO-BC 2022 - 3 weeks (NewC3)
|
trastuzumab + atezolizumab + pertuzumab Resistant: C3 – Early Trials
ESMO-BC 2022 - 3 weeks - (New C3)
|
SMARCA4 deletion
|
NSCLC
|
SMARCA4 deletion
|
NSCLC
|
PD-L1 inhibitor Resistant: C3 – Early Trials
Lung Cancer - 3 weeks (NewC3)
|
PD-L1 inhibitor Resistant: C3 – Early Trials
Lung Cancer - 3 weeks - (New C3)
|
EGFR expression
|
Nasopharyngeal Carcinoma
|
EGFR expression
|
Nasopharyngeal Carcinoma
|
MRG003 Sensitive: C3 – Early Trials
JAMA Oncol - 3 weeks (NewC3)
|
MRG003 Sensitive: C3 – Early Trials
JAMA Oncol - 3 weeks - (New C3)
|
EGFR expression
|
SCCHN
|
EGFR expression
|
SCCHN
|
MRG003 Sensitive: C3 – Early Trials
JAMA Oncol - 3 weeks (NewC3)
|
MRG003 Sensitive: C3 – Early Trials
JAMA Oncol - 3 weeks - (New C3)
|
EGFR T790M
|
LUAD
|
EGFR T790M
|
LUAD
|
EGFR inhibitor Sensitive: C3 – Early Trials
PLoS One - 3 weeks (NewC3)
|
EGFR inhibitor Sensitive: C3 – Early Trials
PLoS One - 3 weeks - (New C3)
|
RAS wild-type
|
CRC
|
RAS wild-type
|
CRC
|
anlotinib Sensitive: C3 – Early Trials
BMC Med - 3 weeks (NewC3)
|
anlotinib Sensitive: C3 – Early Trials
BMC Med - 3 weeks - (New C3)
|
HER-2 778insGSP
|
Breast Cancer
|
HER-2 778insGSP
|
Breast Cancer
|
trastuzumab + everolimus Sensitive: C3 – Early Trials
Transl Oncol - 3 weeks (NewC3)
|
trastuzumab + everolimus Sensitive: C3 – Early Trials
Transl Oncol - 3 weeks - (New C3)
|
HER-2 S310F
|
Breast Cancer
|
HER-2 S310F
|
Breast Cancer
|
trastuzumab + everolimus Sensitive: C3 – Early Trials
Transl Oncol - 3 weeks (NewC3)
|
trastuzumab + everolimus Sensitive: C3 – Early Trials
Transl Oncol - 3 weeks - (New C3)
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
RP6530 Sensitive: C3 – Early Trials
Ann Oncol - 3 weeks (NewC3)
|
RP6530 Sensitive: C3 – Early Trials
Ann Oncol - 3 weeks - (New C3)
|
HRD + BRCA wild-type
|
Triple Negative Breast Cancer
|
HRD + BRCA wild-type
|
Triple Negative Breast Cancer
|
D19466 Sensitive: C3 – Early Trials
Ther Adv Med Oncol - 3 weeks (NewC3)
|
D19466 Sensitive: C3 – Early Trials
Ther Adv Med Oncol - 3 weeks - (New C3)
|
HRD + BRCA wild-type
|
Triple Negative Breast Cancer
|
HRD + BRCA wild-type
|
Triple Negative Breast Cancer
|
carboplatin Sensitive: C3 – Early Trials
Ther Adv Med Oncol - 3 weeks (NewC3)
|
carboplatin Sensitive: C3 – Early Trials
Ther Adv Med Oncol - 3 weeks - (New C3)
|
HRD
|
Triple Negative Breast Cancer
|
HRD
|
Triple Negative Breast Cancer
|
D19466 Sensitive: C3 – Early Trials
Ther Adv Med Oncol - 3 weeks (NewC3)
|
D19466 Sensitive: C3 – Early Trials
Ther Adv Med Oncol - 3 weeks - (New C3)
|
HRD + BRCA wild-type
|
Triple Negative Breast Cancer
|
HRD + BRCA wild-type
|
Triple Negative Breast Cancer
|
cisplatin Sensitive: C3 – Early Trials
Ther Adv Med Oncol - 3 weeks (NewC3)
|
cisplatin Sensitive: C3 – Early Trials
Ther Adv Med Oncol - 3 weeks - (New C3)
|
HRD
|
Triple Negative Breast Cancer
|
HRD
|
Triple Negative Breast Cancer
|
carboplatin Sensitive: C3 – Early Trials
Ther Adv Med Oncol - 3 weeks (NewC3)
|
carboplatin Sensitive: C3 – Early Trials
Ther Adv Med Oncol - 3 weeks - (New C3)
|
TMB-H + PD-L1 expression
|
Soft Tissue Sarcoma
|
TMB-H + PD-L1 expression
|
Soft Tissue Sarcoma
|
anlotinib + toripalimab Sensitive: C4 – Case Studies
Front Immunol - 3 weeks (NewC4)
|
anlotinib + toripalimab Sensitive: C4 – Case Studies
Front Immunol - 3 weeks - (New C4)
|
ER positive
|
HER2 Positive Breast Cancer
|
ER positive
|
HER2 Positive Breast Cancer
|
tucatinib Sensitive: D – Preclinical
Mol Cancer Ther - 3 weeks (NewD)
|
tucatinib Sensitive: D – Preclinical
Mol Cancer Ther - 3 weeks - (New D)
|
TP53 mutation
|
Neurofibrosarcoma
|
TP53 mutation
|
Neurofibrosarcoma
|
AZD1775 Sensitive: D – Preclinical
Mol Cancer Ther - 3 weeks (NewD)
|
AZD1775 Sensitive: D – Preclinical
Mol Cancer Ther - 3 weeks - (New D)
|
ADAM9 expression
|
Solid Tumor
|
ADAM9 expression
|
Solid Tumor
|
IMGC936 Sensitive: D – Preclinical
Mol Cancer Ther - 3 weeks (NewD)
|
IMGC936 Sensitive: D – Preclinical
Mol Cancer Ther - 3 weeks - (New D)
|
ERBB3 mutation
|
Breast Cancer
|
ERBB3 mutation
|
Breast Cancer
|
U3-1402 Sensitive: D – Preclinical
PLoS One - 3 weeks (NewD)
|
U3-1402 Sensitive: D – Preclinical
PLoS One - 3 weeks - (New D)
|
ALDH1A1 positive
|
Triple Negative Breast Cancer
|
ALDH1A1 positive
|
Triple Negative Breast Cancer
|
EPZ-5676 Sensitive: D – Preclinical
Clin Cancer Res - 3 weeks (NewD)
|
EPZ-5676 Sensitive: D – Preclinical
Clin Cancer Res - 3 weeks - (New D)
|
MYC overexpression
|
NSCLC
|
MYC overexpression
|
NSCLC
|
ROS1 inhibitor Resistant: D – Preclinical
Mol Cancer Res - 3 weeks (NewD)
|
ROS1 inhibitor Resistant: D – Preclinical
Mol Cancer Res - 3 weeks - (New D)
|
HER-2 positive
|
Ovarian Cancer
|
HER-2 positive
|
Ovarian Cancer
|
EDIT-202 Sensitive: D – Preclinical
ASGCT 2022 - 3 weeks (NewD)
|
EDIT-202 Sensitive: D – Preclinical
ASGCT 2022 - 3 weeks - (New D)
|
ROR1 positive
|
NSCLC
|
ROR1 positive
|
NSCLC
|
LYL797 Sensitive: D – Preclinical
ASGCT 2022 - 3 weeks (NewD)
|
LYL797 Sensitive: D – Preclinical
ASGCT 2022 - 3 weeks - (New D)
|
ROR1 positive
|
Solid Tumor
|
ROR1 positive
|
Solid Tumor
|
LYL797 Sensitive: D – Preclinical
ASGCT 2022 - 3 weeks (NewD)
|
LYL797 Sensitive: D – Preclinical
ASGCT 2022 - 3 weeks - (New D)
|
TPBG expression
|
AML
|
TPBG expression
|
AML
|
OXB-302 Sensitive: D – Preclinical
ASGCT 2022 - 3 weeks (NewD)
|
OXB-302 Sensitive: D – Preclinical
ASGCT 2022 - 3 weeks - (New D)
|
IDH1 mutation + ATRX deletion + TP53 deletion
|
Glioma
|
IDH1 mutation + ATRX deletion + TP53 deletion
|
Glioma
|
CAN-3110 Sensitive: D – Preclinical
ASGCT 2022 - 3 weeks (NewD)
|
CAN-3110 Sensitive: D – Preclinical
ASGCT 2022 - 3 weeks - (New D)
|
MET amplification
|
CRC
|
MET amplification
|
CRC
|
cabozantinib tablet Sensitive: D – Preclinical
J Pediatr Hematol Oncol - 3 weeks (NewD)
|
cabozantinib tablet Sensitive: D – Preclinical
J Pediatr Hematol Oncol - 3 weeks - (New D)
|
No biomarker
|
Marginal Zone Lymphoma
|
No biomarker
|
Marginal Zone Lymphoma
|
zanubrutinib Sensitive: A1 - Approval
|
zanubrutinib Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
pomalidomide + elotuzumab Sensitive: A1 - Approval
|
pomalidomide + elotuzumab Sensitive: A1 - Approval
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
lisocabtagene maraleucel Sensitive: A1 - Approval
|
lisocabtagene maraleucel Sensitive: A1 - Approval
|
CD20 positive
|
CLL
|
CD20 positive
|
CLL
|
Truxima (rituximab biosimilar) Sensitive: A1 - Approval
|
Truxima (rituximab biosimilar) Sensitive: A1 - Approval
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
afatinib Sensitive: A1 - Approval
|
afatinib Sensitive: A1 - Approval
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
osimertinib Sensitive: A1 - Approval
|
osimertinib Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
ramucirumab Sensitive: A1 - Approval
|
ramucirumab Sensitive: A1 - Approval
|
MSI-H/dMMR
|
Small Intestinal Carcinoma
|
MSI-H/dMMR
|
Small Intestinal Carcinoma
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
gefitinib Sensitive: A1 - Approval
|
gefitinib Sensitive: A1 - Approval
|
PD-L1 expression
|
Triple Negative Breast Cancer
|
PD-L1 expression
|
Triple Negative Breast Cancer
|
atezolizumab Sensitive: A1 - Approval
|
atezolizumab Sensitive: A1 - Approval
|
EGFR L858R
|
NSCLC
|
EGFR L858R
|
NSCLC
|
afatinib Sensitive: A1 - Approval
|
afatinib Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
durvalumab Sensitive: A1 - Approval
|
durvalumab Sensitive: A1 - Approval
|
KIT positive
|
GIST
|
KIT positive
|
GIST
|
imatinib Sensitive: A1 - Approval
|
imatinib Sensitive: A1 - Approval
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
margetuximab Sensitive: A1 - Approval
|
margetuximab Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
No biomarker
|
RCC
|
nivolumab + cabozantinib tablet Sensitive: A1 - Approval
|
nivolumab + cabozantinib tablet Sensitive: A1 - Approval
|
No biomarker
|
Malignant Pleural Mesothelioma
|
No biomarker
|
Malignant Pleural Mesothelioma
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
PD-L1 expression
|
NSCLC
|
PD-L1 expression
|
NSCLC
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
ALK fusion
|
NSCLC
|
ALK fusion
|
NSCLC
|
brigatinib Sensitive: A1 - Approval
|
brigatinib Sensitive: A1 - Approval
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
trastuzumab Sensitive: A1 - Approval
|
trastuzumab Sensitive: A1 - Approval
|
No biomarker
|
Follicular Lymphoma
|
No biomarker
|
Follicular Lymphoma
|
axicabtagene ciloleucel Sensitive: A1 - Approval
|
axicabtagene ciloleucel Sensitive: A1 - Approval
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
axicabtagene ciloleucel Sensitive: A1 - Approval
|
axicabtagene ciloleucel Sensitive: A1 - Approval
|
No biomarker
|
Mediastinal B Cell Lymphoma
|
No biomarker
|
Mediastinal B Cell Lymphoma
|
axicabtagene ciloleucel Sensitive: A1 - Approval
|
axicabtagene ciloleucel Sensitive: A1 - Approval
|
PDGFRA D842V
|
GIST
|
PDGFRA D842V
|
GIST
|
avapritinib Sensitive: A1 - Approval
|
avapritinib Sensitive: A1 - Approval
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
No biomarker
|
Esophageal Cancer
|
No biomarker
|
Esophageal Cancer
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
niraparib Sensitive: A1 - Approval
|
niraparib Sensitive: A1 - Approval
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
niraparib Sensitive: A1 - Approval
|
niraparib Sensitive: A1 - Approval
|
No biomarker
|
Peritoneal Cancer
|
No biomarker
|
Peritoneal Cancer
|
niraparib Sensitive: A1 - Approval
|
niraparib Sensitive: A1 - Approval
|
No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
brexucabtagene autoleucel Sensitive: A1 - Approval
|
brexucabtagene autoleucel Sensitive: A1 - Approval
|
KRAS G12C
|
NSCLC
|
KRAS G12C
|
NSCLC
|
sotorasib Sensitive: A1 - Approval
|
sotorasib Sensitive: A1 - Approval
|
PD-L1 expression
|
NSCLC
|
PD-L1 expression
|
NSCLC
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
EGFR L858R
|
NSCLC
|
EGFR L858R
|
NSCLC
|
osimertinib Sensitive: A1 - Approval
|
osimertinib Sensitive: A1 - Approval
|
MSI-H/dMMR
|
Solid Tumor
|
MSI-H/dMMR
|
Solid Tumor
|
dostarlimab Sensitive: A1 - Approval
|
dostarlimab Sensitive: A1 - Approval
|
No biomarker
|
Esophageal Adenocarcinoma
|
No biomarker
|
Esophageal Adenocarcinoma
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
No biomarker
|
NHL
|
No biomarker
|
NHL
|
brentuximab vedotin Sensitive: A1 - Approval
|
brentuximab vedotin Sensitive: A1 - Approval
|
ALK positive
|
NSCLC
|
ALK positive
|
NSCLC
|
brigatinib Sensitive: A1 - Approval
|
brigatinib Sensitive: A1 - Approval
|
ROS1 fusion
|
NSCLC
|
ROS1 fusion
|
NSCLC
|
entrectinib Sensitive: A1 - Approval
|
entrectinib Sensitive: A1 - Approval
|
No biomarker
|
Gastric Cancer
|
No biomarker
|
Gastric Cancer
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
MET exon 14 mutation
|
NSCLC
|
MET exon 14 mutation
|
NSCLC
|
tepotinib Sensitive: A1 - Approval
|
tepotinib Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
bevacizumab Sensitive: A1 - Approval
|
bevacizumab Sensitive: A1 - Approval
|
ALK positive
|
NHL
|
ALK positive
|
NHL
|
crizotinib Sensitive: A1 - Approval
|
crizotinib Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
EGFR L858R
|
NSCLC
|
EGFR L858R
|
NSCLC
|
dacomitinib Sensitive: A1 - Approval
|
dacomitinib Sensitive: A1 - Approval
|
No biomarker
|
Small Cell Lung Cancer
|
No biomarker
|
Small Cell Lung Cancer
|
durvalumab Sensitive: A1 - Approval
|
durvalumab Sensitive: A1 - Approval
|
EGFR T790M
|
NSCLC
|
EGFR T790M
|
NSCLC
|
lazertinib Sensitive: A1 - Approval
|
lazertinib Sensitive: A1 - Approval
|
EGFR exon 19 deletion
|
NSCLC
|
EGFR exon 19 deletion
|
NSCLC
|
dacomitinib Sensitive: A1 - Approval
|
dacomitinib Sensitive: A1 - Approval
|
MET exon 14 mutation
|
NSCLC
|
MET exon 14 mutation
|
NSCLC
|
capmatinib Sensitive: A1 - Approval
|
capmatinib Sensitive: A1 - Approval
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
cemiplimab Sensitive: A1 - Approval
|
cemiplimab Sensitive: A1 - Approval
|
RET fusion
|
NSCLC
|
RET fusion
|
NSCLC
|
pralsetinib Sensitive: A1 - Approval
|
pralsetinib Sensitive: A1 - Approval
|
No biomarker
|
SCCHN
|
No biomarker
|
SCCHN
|
cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval
|
cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval
|
No biomarker
|
Gastric Adenocarcinoma
|
No biomarker
|
Gastric Adenocarcinoma
|
cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval
|
cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval
|
cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
cisplatin + pemetrexed Sensitive: A1 - Approval
|
cisplatin + pemetrexed Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive: A1 - Approval
|
docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive: A1 - Approval
|
No biomarker
|
BCC
|
No biomarker
|
BCC
|
fluorouracil topical Sensitive: A1 - Approval
|
fluorouracil topical Sensitive: A1 - Approval
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
PD-L1 expression
|
Esophageal Squamous Cell Carcinoma
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
PD-L1 expression
|
Urothelial Cancer
|
PD-L1 expression
|
Urothelial Cancer
|
atezolizumab Sensitive: A1 - Approval
|
atezolizumab Sensitive: A1 - Approval
|
EGFR mutation
|
NSCLC
|
EGFR mutation
|
NSCLC
|
gefitinib Sensitive: A1 - Approval
|
gefitinib Sensitive: A1 - Approval
|
EGFR L858R
|
NSCLC
|
EGFR L858R
|
NSCLC
|
gefitinib Sensitive: A1 - Approval
|
gefitinib Sensitive: A1 - Approval
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
cisplatin Sensitive: A1 - Approval
|
cisplatin Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
carfilzomib Sensitive: A1 - Approval
|
carfilzomib Sensitive: A1 - Approval
|
No biomarker
|
Thyroid Gland Medullary Carcinoma
|
No biomarker
|
Thyroid Gland Medullary Carcinoma
|
cabozantinib capsule Sensitive: A1 - Approval
|
cabozantinib capsule Sensitive: A1 - Approval
|
ALK positive
|
NSCLC
|
ALK positive
|
NSCLC
|
crizotinib Sensitive: A1 - Approval
|
crizotinib Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
ROS1 positive
|
NSCLC
|
ROS1 positive
|
NSCLC
|
crizotinib Sensitive: A1 - Approval
|
crizotinib Sensitive: A1 - Approval
|
RET fusion
|
NSCLC
|
RET fusion
|
NSCLC
|
selpercatinib Sensitive: A1 - Approval
|
selpercatinib Sensitive: A1 - Approval
|
EGFR mutation
|
NSCLC
|
EGFR mutation
|
NSCLC
|
afatinib Sensitive: A1 - Approval
|
afatinib Sensitive: A1 - Approval
|
EGFR exon 20 insertion
|
NSCLC
|
EGFR exon 20 insertion
|
NSCLC
|
mobocertinib Sensitive: A1 - Approval
|
mobocertinib Sensitive: A1 - Approval
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
atezolizumab Sensitive: A1 - Approval
|
atezolizumab Sensitive: A1 - Approval
|
No biomarker
|
Small Cell Lung Cancer
|
No biomarker
|
Small Cell Lung Cancer
|
atezolizumab Sensitive: A1 - Approval
|
atezolizumab Sensitive: A1 - Approval
|
HER-2 positive
|
Gastric Cancer
|
HER-2 positive
|
Gastric Cancer
|
fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval
|
fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 positive
|
Gastroesophageal Junction Adenocarcinoma
|
fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval
|
fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval
|
BRCA2 mutation
|
Pancreatic Cancer
|
BRCA2 mutation
|
Pancreatic Cancer
|
olaparib Sensitive: A1 - Approval
|
olaparib Sensitive: A1 - Approval
|
IDH2 mutation
|
AML
|
IDH2 mutation
|
AML
|
enasidenib Sensitive: A1 - Approval
|
enasidenib Sensitive: A1 - Approval
|
No biomarker
|
AML
|
No biomarker
|
AML
|
glasdegib Sensitive: A1 - Approval
|
glasdegib Sensitive: A1 - Approval
|
EGFR mutation
|
NSCLC
|
EGFR mutation
|
NSCLC
|
erlotinib Sensitive: A1 - Approval
|
erlotinib Sensitive: A1 - Approval
|
PD-L1 overexpression
|
NSCLC
|
PD-L1 overexpression
|
NSCLC
|
atezolizumab Sensitive: A1 - Approval
|
atezolizumab Sensitive: A1 - Approval
|
No biomarker
|
HCC
|
No biomarker
|
HCC
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
No biomarker
|
HCC
|
No biomarker
|
HCC
|
bevacizumab + atezolizumab Sensitive: A1 - Approval
|
bevacizumab + atezolizumab Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
bortezomib + panobinostat Sensitive: A1 - Approval
|
bortezomib + panobinostat Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
bortezomib + pegylated liposomal doxorubicin Sensitive: A1 - Approval
|
bortezomib + pegylated liposomal doxorubicin Sensitive: A1 - Approval
|
BRCA1 mutation
|
Pancreatic Cancer
|
BRCA1 mutation
|
Pancreatic Cancer
|
olaparib Sensitive: A1 - Approval
|
olaparib Sensitive: A1 - Approval
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
rituximab Sensitive: A1 - Approval
|
rituximab Sensitive: A1 - Approval
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
HER-2 positive
|
HER2 Positive Breast Cancer
|
ado-trastuzumab emtansine Sensitive: A1 - Approval
|
ado-trastuzumab emtansine Sensitive: A1 - Approval
|
RET fusion
|
Thyroid Gland Carcinoma
|
RET fusion
|
Thyroid Gland Carcinoma
|
pralsetinib Sensitive: A1 - Approval
|
pralsetinib Sensitive: A1 - Approval
|
FGFR2 rearrangement
|
Cholangiocarcinoma
|
FGFR2 rearrangement
|
Cholangiocarcinoma
|
infigratinib Sensitive: A1 - Approval
|
infigratinib Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
tislelizumab Sensitive: A1 - Approval
|
tislelizumab Sensitive: A1 - Approval
|
No biomarker
|
Lymphoma
|
No biomarker
|
Lymphoma
|
axicabtagene ciloleucel Resistant: A1 - Approval
|
axicabtagene ciloleucel Resistant: A1 - Approval
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
tisagenlecleucel-T Sensitive: A1 - Approval
|
tisagenlecleucel-T Sensitive: A1 - Approval
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
tisagenlecleucel-T Sensitive: A1 - Approval
|
tisagenlecleucel-T Sensitive: A1 - Approval
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
tisagenlecleucel-T Sensitive: A1 - Approval
|
tisagenlecleucel-T Sensitive: A1 - Approval
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
apalutamide Sensitive: A1 - Approval
|
apalutamide Sensitive: A1 - Approval
|
